PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26656789-1 2016 BACKGROUND: The enzyme Arylsulfatase B (ARSB; N-acetylgalactosamine 4-sulfatase), is required for degradation of sulfated glycosaminoglycans (GAGs) which accumulate in cystic fibrosis. Glycosaminoglycans 122-140 arylsulfatase B Homo sapiens 40-44 29762123-3 2018 Arylsulfatase B (ARSB) selectively cleaves 4S groups from the non-reducing ends of GAG chains without disrupting other, growth-permissive motifs. Glycosaminoglycans 83-86 arylsulfatase B Homo sapiens 0-15 29762123-3 2018 Arylsulfatase B (ARSB) selectively cleaves 4S groups from the non-reducing ends of GAG chains without disrupting other, growth-permissive motifs. Glycosaminoglycans 83-86 arylsulfatase B Homo sapiens 17-21 27078017-1 2016 Arylsulfatase B (B-acetylgalactosamine 4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from the non-reducing end of the glycosaminoglycans chondroitin 4-sulfate and dermatan sulfate. Glycosaminoglycans 135-153 arylsulfatase B Homo sapiens 0-15 27078017-1 2016 Arylsulfatase B (B-acetylgalactosamine 4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from the non-reducing end of the glycosaminoglycans chondroitin 4-sulfate and dermatan sulfate. Glycosaminoglycans 135-153 arylsulfatase B Homo sapiens 52-56 26450354-9 2016 Two patients, both with high baseline glycosaminoglycan levels in their urine and severe mutations in the arylsulfatase B gene, scored clearly lower than expected. Glycosaminoglycans 38-55 arylsulfatase B Homo sapiens 106-121 33985463-2 2021 MPS VI is a multisystemic disease resulting from a deficiency in arylsulfatase B causing an accumulation of glycosaminoglycans in the tissues and organs of the body. Glycosaminoglycans 108-126 arylsulfatase B Homo sapiens 65-80 29371215-2 2018 In the monogenic disease mucopolysaccharidosis VI, loss-of-function mutations in arylsulfatase B lead to myocardial accumulation of chondroitin sulfate (CS) glycosaminoglycans, manifesting as myriad cardiac symptoms. Glycosaminoglycans 157-175 arylsulfatase B Homo sapiens 81-96 25190157-16 2014 Both the radiological findings and increased urine GAG are important clues to diagnose MPS VI.Large decrease or absence of ARSB activity is diagnostic for MPS VI.Four novel mutations of ARSB gene were identified. Glycosaminoglycans 51-54 arylsulfatase B Homo sapiens 186-190 24107440-2 2013 Dysfunctional ARSB causes lysosomal accumulation of glycosaminoglycans (GAG). Glycosaminoglycans 52-70 arylsulfatase B Homo sapiens 14-18 24107440-2 2013 Dysfunctional ARSB causes lysosomal accumulation of glycosaminoglycans (GAG). Glycosaminoglycans 72-75 arylsulfatase B Homo sapiens 14-18 22550062-1 2013 The enzyme Arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) removes 4-sulfate groups from chondroitin-4-sulfate and dermatan sulfate and is required for the degradation of these sulfated glycosaminoglycans (sGAGs). Glycosaminoglycans 196-214 arylsulfatase B Homo sapiens 11-26 22550062-1 2013 The enzyme Arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) removes 4-sulfate groups from chondroitin-4-sulfate and dermatan sulfate and is required for the degradation of these sulfated glycosaminoglycans (sGAGs). Glycosaminoglycans 196-214 arylsulfatase B Homo sapiens 28-32 22550062-1 2013 The enzyme Arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) removes 4-sulfate groups from chondroitin-4-sulfate and dermatan sulfate and is required for the degradation of these sulfated glycosaminoglycans (sGAGs). Glycosaminoglycans 196-214 arylsulfatase B Homo sapiens 34-67 21930407-1 2011 Mucopolysaccharidosis type VI (MPS VI) is a progressive, multisystem autosomal recessive lysosomal disorder resulting from deficient N-acetylgalactosamine-4-sulphatase (ASB) and the consequent accumulation of glycosaminoglycan (GAG). Glycosaminoglycans 209-226 arylsulfatase B Homo sapiens 169-172 22289849-1 2012 INTRODUCTION: Mucopolysaccharidosis VI (MPS-VI) is caused by a deficiency in N-acetylgalactosamine-4-sulfatase activity, resulting in lysosomal accumulation of partially degraded glycosaminoglycans (GAGs). Glycosaminoglycans 179-197 arylsulfatase B Homo sapiens 77-110 22428001-7 2012 Hypoxia, like ARSB silencing, significantly increased the total cellular sulfated glycosaminoglycans and chondroitin-4-sulfate (C4S) content. Glycosaminoglycans 82-100 arylsulfatase B Homo sapiens 14-18 21930407-1 2011 Mucopolysaccharidosis type VI (MPS VI) is a progressive, multisystem autosomal recessive lysosomal disorder resulting from deficient N-acetylgalactosamine-4-sulphatase (ASB) and the consequent accumulation of glycosaminoglycan (GAG). Glycosaminoglycans 228-231 arylsulfatase B Homo sapiens 169-172 20036175-1 2010 In mucopolysaccharidosis VI, or Maroteaux-Lamy syndrome, deficiency of N-acetylgalactosamine 4-sulfatase leads to storage of glycosaminoglycans (GAGs) and MPS VI patients often develop spinal cord compression during the course of the disease due to GAG storage within the cervical meninges, requiring neurosurgical intervention, as intravenous (IV) enzyme replacement therapy (ERT) is not expected to cross the blood-brain barrier. Glycosaminoglycans 125-143 arylsulfatase B Homo sapiens 71-104 20800524-1 2010 BACKGROUND: Maroteaux-Lamy syndrome, or mucopolysaccharidosis (MPS) type VI, is the autosomal recessive lysosomal disorder resulting from deficient N-acetylgalactosamine 4-sulfatase (ARSB) and the consequent accumulation of glycosaminoglycan (GAG). Glycosaminoglycans 224-241 arylsulfatase B Homo sapiens 148-181 20800524-1 2010 BACKGROUND: Maroteaux-Lamy syndrome, or mucopolysaccharidosis (MPS) type VI, is the autosomal recessive lysosomal disorder resulting from deficient N-acetylgalactosamine 4-sulfatase (ARSB) and the consequent accumulation of glycosaminoglycan (GAG). Glycosaminoglycans 224-241 arylsulfatase B Homo sapiens 183-187 20800524-1 2010 BACKGROUND: Maroteaux-Lamy syndrome, or mucopolysaccharidosis (MPS) type VI, is the autosomal recessive lysosomal disorder resulting from deficient N-acetylgalactosamine 4-sulfatase (ARSB) and the consequent accumulation of glycosaminoglycan (GAG). Glycosaminoglycans 243-246 arylsulfatase B Homo sapiens 148-181 20800524-1 2010 BACKGROUND: Maroteaux-Lamy syndrome, or mucopolysaccharidosis (MPS) type VI, is the autosomal recessive lysosomal disorder resulting from deficient N-acetylgalactosamine 4-sulfatase (ARSB) and the consequent accumulation of glycosaminoglycan (GAG). Glycosaminoglycans 243-246 arylsulfatase B Homo sapiens 183-187 21813902-10 2011 Recombinant human arylsulfatase B significantly improves endurance and reduces urinary glycosaminoglycan excretion. Glycosaminoglycans 87-104 arylsulfatase B Homo sapiens 18-33 21378286-1 2011 The enzyme arylsulfatase B (N-acetylgalactosamine-4-sulfatase; ARSB; ASB) removes 4-sulfate groups from the sulfated glycosaminoglycans (sGAG) chondroitin-4-sulfate (C4S) and dermatan sulfate (DS). Glycosaminoglycans 117-135 arylsulfatase B Homo sapiens 28-61 21378286-1 2011 The enzyme arylsulfatase B (N-acetylgalactosamine-4-sulfatase; ARSB; ASB) removes 4-sulfate groups from the sulfated glycosaminoglycans (sGAG) chondroitin-4-sulfate (C4S) and dermatan sulfate (DS). Glycosaminoglycans 117-135 arylsulfatase B Homo sapiens 63-67 21378286-1 2011 The enzyme arylsulfatase B (N-acetylgalactosamine-4-sulfatase; ARSB; ASB) removes 4-sulfate groups from the sulfated glycosaminoglycans (sGAG) chondroitin-4-sulfate (C4S) and dermatan sulfate (DS). Glycosaminoglycans 117-135 arylsulfatase B Homo sapiens 69-72 20036175-1 2010 In mucopolysaccharidosis VI, or Maroteaux-Lamy syndrome, deficiency of N-acetylgalactosamine 4-sulfatase leads to storage of glycosaminoglycans (GAGs) and MPS VI patients often develop spinal cord compression during the course of the disease due to GAG storage within the cervical meninges, requiring neurosurgical intervention, as intravenous (IV) enzyme replacement therapy (ERT) is not expected to cross the blood-brain barrier. Glycosaminoglycans 145-148 arylsulfatase B Homo sapiens 71-104 19682969-1 2009 A functional bioassay has been developed for measuring the intracellular activity of recombinant human arylsulfatase B (rhASB) on its natural glycosaminoglycan (GAG) substrates, dermatan sulfate (DS), and chondroitin sulfate (CS) when the enzyme is taken up into cultured ASB-deficient human fibroblasts (GM00519). Glycosaminoglycans 142-159 arylsulfatase B Homo sapiens 103-118 19682969-2 2009 The enzyme ASB is a lysosomal exohydrolase, cleaving sulfate from the N-acetylgalactosamine-4-sulfate (GalNAc-4S) residue at the nonreducing terminal of GAG structures. Glycosaminoglycans 153-156 arylsulfatase B Homo sapiens 11-14 19682969-1 2009 A functional bioassay has been developed for measuring the intracellular activity of recombinant human arylsulfatase B (rhASB) on its natural glycosaminoglycan (GAG) substrates, dermatan sulfate (DS), and chondroitin sulfate (CS) when the enzyme is taken up into cultured ASB-deficient human fibroblasts (GM00519). Glycosaminoglycans 142-159 arylsulfatase B Homo sapiens 122-125 19682969-1 2009 A functional bioassay has been developed for measuring the intracellular activity of recombinant human arylsulfatase B (rhASB) on its natural glycosaminoglycan (GAG) substrates, dermatan sulfate (DS), and chondroitin sulfate (CS) when the enzyme is taken up into cultured ASB-deficient human fibroblasts (GM00519). Glycosaminoglycans 161-164 arylsulfatase B Homo sapiens 103-118 19682969-1 2009 A functional bioassay has been developed for measuring the intracellular activity of recombinant human arylsulfatase B (rhASB) on its natural glycosaminoglycan (GAG) substrates, dermatan sulfate (DS), and chondroitin sulfate (CS) when the enzyme is taken up into cultured ASB-deficient human fibroblasts (GM00519). Glycosaminoglycans 161-164 arylsulfatase B Homo sapiens 122-125 16549525-4 2006 Clearance of glycosaminoglycans from chondrocytes was observed at a dose of 10 microg recombinant human N-acetylgalactosamine-4-sulfatase (rh4S), but greater clearance was observed with higher doses. Glycosaminoglycans 13-31 arylsulfatase B Homo sapiens 104-137 17458871-2 2007 ARSB is a lysosomal enzyme involved in the degradation of the glycosaminoglycans (GAG) dermatan and chondroitin sulfate. Glycosaminoglycans 62-80 arylsulfatase B Homo sapiens 0-4 17458871-2 2007 ARSB is a lysosomal enzyme involved in the degradation of the glycosaminoglycans (GAG) dermatan and chondroitin sulfate. Glycosaminoglycans 82-85 arylsulfatase B Homo sapiens 0-4 17458871-3 2007 ARSB mutations reduce enzyme function and GAG degradation, causing lysosomal storage and urinary excretion of these partially degraded substrates. Glycosaminoglycans 42-45 arylsulfatase B Homo sapiens 0-4 18285341-3 2008 To determine if expression of ASB and GALNS impacts on glycosaminoglycans (GAGs) and proteoglycans beyond their association with the mucopolysaccharidoses, we modified the expression of ASB and GALNS by overexpression and by silencing with small interference RNA in MCF-7 cells. Glycosaminoglycans 55-73 arylsulfatase B Homo sapiens 30-33 17672828-1 2008 MPS VI (mucopolysaccharidosis type VI) is a lysosomal storage disease in which deficient activity of the enzyme N-acetylgalactosamine 4-sulfatase [ASB (arylsulfatase B)] impairs the stepwise degradation of the GAG (glycosaminoglycan) dermatan sulfate. Glycosaminoglycans 210-213 arylsulfatase B Homo sapiens 112-145 17672828-1 2008 MPS VI (mucopolysaccharidosis type VI) is a lysosomal storage disease in which deficient activity of the enzyme N-acetylgalactosamine 4-sulfatase [ASB (arylsulfatase B)] impairs the stepwise degradation of the GAG (glycosaminoglycan) dermatan sulfate. Glycosaminoglycans 210-213 arylsulfatase B Homo sapiens 147-150 17672828-1 2008 MPS VI (mucopolysaccharidosis type VI) is a lysosomal storage disease in which deficient activity of the enzyme N-acetylgalactosamine 4-sulfatase [ASB (arylsulfatase B)] impairs the stepwise degradation of the GAG (glycosaminoglycan) dermatan sulfate. Glycosaminoglycans 210-213 arylsulfatase B Homo sapiens 152-167 11668612-2 2001 Mutations in the 4S gene are responsible for 4S deficiency, which leads to the intralysosomal storage of partially degraded glycosaminoglycans, dermatan sulfate, and chondroitin 4-sulfate. Glycosaminoglycans 124-142 arylsulfatase B Homo sapiens 17-19 11668612-2 2001 Mutations in the 4S gene are responsible for 4S deficiency, which leads to the intralysosomal storage of partially degraded glycosaminoglycans, dermatan sulfate, and chondroitin 4-sulfate. Glycosaminoglycans 124-142 arylsulfatase B Homo sapiens 45-47 9364929-0 1997 Feline mucopolysaccharidosis type VI: correction of glycosaminoglycan storage in myoblasts by retrovirus-mediated transfer of the feline N-acetylgalactosamine 4-sulfatase gene. Glycosaminoglycans 52-69 arylsulfatase B Homo sapiens 137-170 9268591-6 1997 Relative proportions of glycosaminoglycans, the natural substrates of beta-glucuronidase and arylsulfatase B, in the retinal pigment epithelium altered with the age of the donors. Glycosaminoglycans 24-42 arylsulfatase B Homo sapiens 93-108 8755662-2 1996 Mucopolysacchariodosis type VI (MPS VI) is the lysosomal storage disorder caused by the deficient activity of arylsulfatase B (ASB; N-acetylgalactosamine 4-sulfatase) and the subsequent accumulation of the glycosaminoglycan (GAG), dermatan sulfate. Glycosaminoglycans 206-223 arylsulfatase B Homo sapiens 110-125 8755662-2 1996 Mucopolysacchariodosis type VI (MPS VI) is the lysosomal storage disorder caused by the deficient activity of arylsulfatase B (ASB; N-acetylgalactosamine 4-sulfatase) and the subsequent accumulation of the glycosaminoglycan (GAG), dermatan sulfate. Glycosaminoglycans 206-223 arylsulfatase B Homo sapiens 127-130 8755662-2 1996 Mucopolysacchariodosis type VI (MPS VI) is the lysosomal storage disorder caused by the deficient activity of arylsulfatase B (ASB; N-acetylgalactosamine 4-sulfatase) and the subsequent accumulation of the glycosaminoglycan (GAG), dermatan sulfate. Glycosaminoglycans 206-223 arylsulfatase B Homo sapiens 132-165 8755662-2 1996 Mucopolysacchariodosis type VI (MPS VI) is the lysosomal storage disorder caused by the deficient activity of arylsulfatase B (ASB; N-acetylgalactosamine 4-sulfatase) and the subsequent accumulation of the glycosaminoglycan (GAG), dermatan sulfate. Glycosaminoglycans 225-228 arylsulfatase B Homo sapiens 110-125 8755662-2 1996 Mucopolysacchariodosis type VI (MPS VI) is the lysosomal storage disorder caused by the deficient activity of arylsulfatase B (ASB; N-acetylgalactosamine 4-sulfatase) and the subsequent accumulation of the glycosaminoglycan (GAG), dermatan sulfate. Glycosaminoglycans 225-228 arylsulfatase B Homo sapiens 127-130 8755662-2 1996 Mucopolysacchariodosis type VI (MPS VI) is the lysosomal storage disorder caused by the deficient activity of arylsulfatase B (ASB; N-acetylgalactosamine 4-sulfatase) and the subsequent accumulation of the glycosaminoglycan (GAG), dermatan sulfate. Glycosaminoglycans 225-228 arylsulfatase B Homo sapiens 132-165 1427856-1 1992 Arylsulfatase B (ARSB) is the lysosomal enzyme that catalyzes the hydrolysis of 4-sulfate groups from N-acetylgalactosamine 4-sulfate moieties on the glycosaminoglycans, dermatan sulfate and chondroitin sulfate A. Glycosaminoglycans 150-168 arylsulfatase B Homo sapiens 0-15 1427856-1 1992 Arylsulfatase B (ARSB) is the lysosomal enzyme that catalyzes the hydrolysis of 4-sulfate groups from N-acetylgalactosamine 4-sulfate moieties on the glycosaminoglycans, dermatan sulfate and chondroitin sulfate A. Glycosaminoglycans 150-168 arylsulfatase B Homo sapiens 17-21 1784840-3 1991 Arylsulfatase B catalyses the desulfation of glycosaminoglycans in the catabolism of the intimal ground substance. Glycosaminoglycans 45-63 arylsulfatase B Homo sapiens 0-15 18418554-1 2009 MPS VI (mucopolysaccharidosis VI, known as Maroteaux-Lamy syndrome) is a multi-systemic inherited disease, resulting from a deficiency of N-acetylgalactosamine-4-sulfatase, causing accumulation of the glycosaminoglycan (GAG) dermatan sulfate in all tissues. Glycosaminoglycans 201-218 arylsulfatase B Homo sapiens 138-171 35118118-1 2021 Mucopolysaccharidosis VI (MPS VI) is an autosomal recessive lysosomal storage disease caused by mutations in the arylsulfatase B gene (ARSB) and consequent deficient activity of ARSB, a lysosomal enzyme involved in the glycosaminoglycan (s) (GAGs) metabolism. Glycosaminoglycans 219-236 arylsulfatase B Homo sapiens 135-139 34435740-2 2021 It is caused by variants in ARSB, which encodes the lysosomal arylsulfatase B (ARSB) enzyme, part of the degradation process of glycosaminoglycans in lysosomes. Glycosaminoglycans 128-146 arylsulfatase B Homo sapiens 28-32 34435740-2 2021 It is caused by variants in ARSB, which encodes the lysosomal arylsulfatase B (ARSB) enzyme, part of the degradation process of glycosaminoglycans in lysosomes. Glycosaminoglycans 128-146 arylsulfatase B Homo sapiens 62-77 34435740-2 2021 It is caused by variants in ARSB, which encodes the lysosomal arylsulfatase B (ARSB) enzyme, part of the degradation process of glycosaminoglycans in lysosomes. Glycosaminoglycans 128-146 arylsulfatase B Homo sapiens 79-83 34948256-3 2021 The enzyme deficit causes a pathological accumulation of the undegraded glycosaminoglycans dermatan-sulphate and chondroitin-sulphate, natural substrates of ASB activity. Glycosaminoglycans 72-90 arylsulfatase B Homo sapiens 157-160 35078524-1 2022 BACKGROUND: Mucopolysaccharidosis VI, or Maroteaux-Lamy disease, is an autosomal recessive disease characterized by deficiency of the enzyme arylsulfatase B in the lysosomal catabolism of glycosaminoglycans. Glycosaminoglycans 188-206 arylsulfatase B Homo sapiens 141-156 35118118-1 2021 Mucopolysaccharidosis VI (MPS VI) is an autosomal recessive lysosomal storage disease caused by mutations in the arylsulfatase B gene (ARSB) and consequent deficient activity of ARSB, a lysosomal enzyme involved in the glycosaminoglycan (s) (GAGs) metabolism. Glycosaminoglycans 219-236 arylsulfatase B Homo sapiens 178-182